A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified food-borne bacteria as a courier to deliver potent cancer-killing proteins into tumor cells.

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S.

After getting engaged, the only words journalist Mrinali Dhembla expected to hear were “I do.” Instead, she was told, “You ...

Mrinali Dhembla, 27, diagnosed with stage-3 colorectal cancer and Lynch syndrome, recovers rapidly after receiving a dual immunotherapy regimen.

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasibin KRAS-mutated colorectal cancer cells - ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

Day One Biopharmaceuticals stock remains a "Strong Buy." Learn more about its outlook, surging revenue, and ADC pipeline catalysts.

FLORENCE, Italy, March 09, 2026 (GLOBE NEWSWIRE) -- 2025 was a 'positive year” for Menarini, which is celebrating its 140th ...